Priority Date: 13.01.12 (US 201261586482P)

FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS

  • Application ID: EP13705582
  • Status: █ APPLICATION DEEMED TO BE WITHDRAWN

Applicant

Technology company logo small
Novartis AG
Technology Company

Attorneys

Missing person image small
Emma Jane Hodge
no operation time available
Novartis Pharma AG
1 office
Technology Company
Missing person image small
Georg von Sprecher
no operation time available
Novartis Pharma AG
1 office
Technology Company

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Novartis Pharma AG is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 231 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 13.01.2012 - Priority Date (US 201261586482P)
  • 18.07.2013 - Publication A1 (WO2013105063)
  • 19.11.2014 - Publication A1 (EP2802583)